Catalent & Sanwa Announce Exclusive License Agreement

Catalent Pharma Solutions and Sanwa Kagaku Kenkyusho Co., Ltd. have recently entered into an exclusive agreement to bring Sanwa’s innovative drug delivery tableting technology to global markets. This novel technology will be marketed by Catalent in all markets outside of Japan, Korea, China (Hong Kong), and Taiwan. OSDrC^® is a fully developed optimized dose delivery technology and has already been commercially proven by Sanwa in Japan. Catalent will now utilize its global footprint, leading modified-release delivery expertise, and integrated manufacturing know-how to bring OSDrC to the global market. This technology enables significant improvements to therapeutic and drug delivery release profiles. It is anticipated that Catalent will commence customer product development trials at its Winchester, KY, facility in January 2012.

OSDrC optimized dose delivery technology enables the design of single or multi-core tablets, with a practically endless variety of core numbers, shapes, sizes, and placement within the tablet. This flexible-core capability offers the broadest available range of controlled-release designs for drug formulators, providing the potential for optimal dosing, therapeutic product profiles, and plasma release profiles to meet patient needs in a high-quality, one-step manufacturing process.

OSDrC technology can produce pulsatile tablets, bi-layer tablets, multi-core tablets, dividable tablets, delayed-release tablets, and direct-compression orally dissolving tablets with better quality and release control design than standard tableting technologies.

This technology expands Catalent’s capabilities in designing pulsatile targeted drug delivery, immediate- and extended-release combination tablets, and combination product tablets containing multiple active drugs. OSDrC, in addition to other recent technology advances at its Winchester, KY, and Schorndorf, Germany, facilities, is part of an overall growth initiative for Catalent to expand its leading modified-release technology capabilities.

“We are excited to partner with Sanwa as we continue to expand and innovate our modified-release technology solutions and manufacturing capabilities,” said Dr. Ian Muir, President of Catalent’s Modified Release Technologies business. “The addition of OSDrC optimized dose delivery technology will enhance Catalent’s ability to solve our customer’s controlled-release formulation challenges – by providing the broadest and highest quality range of drug delivery technologies and scientific expertise in the industry. It is a perfect fit with our existing controlled-release, Zydis^® and Lyopan^® fast-dissolve, and Stick Pack modified-release technology platform to enhance our ability to bring more products and better treatments to the market.”

“OSDrC technology already has an existing application in the Japanese market,” added Mr. Kazuo Yamamoto, President of Sanwa. Catalent’s global presence, modified-release technology scientific expertise, and integrated manufacturing and packaging services make them the ideal partner for Sanwa as we make this innovative technology available for global customers to improve their products.”

Michael J. Valazza, RPh, Global Vice President of Catalent’s Modified Release Technologies business, will be presenting this new technology at the 38^th Annual Controlled Release Society Conference on Sunday, July 31 from 8:30-9:30 AM at the Gaylord National Hotel and Convention Center in National Harbor, MD. If you would like to conduct any follow-up interviews or learn more about OSDrC technology, please contact Patricia McGee at patricia.mcgee@catalent.com. To learn more about Catalent’s modified-release technologies, please visit www.catalent.com/OSDrC.